Literature DB >> 26781577

Release of Enterococcus mundtii Bacteriocin ST4SA from Self-Setting Brushite Bone Cement.

Anton D van Staden1, Tiaan D J Heunis1, Leon M T Dicks2,3.   

Abstract

Maxillofacial and craniofacial surgery is on the increase, which exposes more patients at risk of acquiring microbial infections. The use of antibiotic-loaded calcium phosphate bone cements has been shown to reduce the incidence of infection. A marked increase in antibiotic-resistant pathogens, including multidrug-resistant pathogens, has been reported. This has led to the investigation of various compounds as alternatives to conventional treatments. In this paper, we report on the incorporation and release of a broad-spectrum class II antimicrobial peptide, bacteriocin ST4SA produced by Enterococcus mundtii, into a calcium orthophosphate-based bone cement. Our results suggest class II bacteriocins may be incorporated into self-setting bone cements to produce implants with antimicrobial activity over extended periods of time.

Entities:  

Keywords:  Antimicrobial activity; Bacteriocin; Brushite bone cement

Year:  2011        PMID: 26781577     DOI: 10.1007/s12602-011-9074-7

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  34 in total

1.  Controlled release of gentamicin from calcium phosphate-poly(lactic acid-co-glycolic acid) composite bone cement.

Authors:  Julia Schnieders; Uwe Gbureck; Roger Thull; Thomas Kissel
Journal:  Biomaterials       Date:  2006-04-18       Impact factor: 12.479

Review 2.  Osteoclasts: structure and function.

Authors:  A M Pierce; S Lindskog; L Hammarström
Journal:  Electron Microsc Rev       Date:  1991

3.  Bioactivity of bone resorptive factor loaded on osteoconductive matrices: stability post-dehydration.

Authors:  Damien Le Nihouannen; Svetlana V Komarova; Uwe Gbureck; Jake E Barralet
Journal:  Eur J Pharm Biopharm       Date:  2008-08-14       Impact factor: 5.571

4.  Gentamicin-loaded hydraulic calcium phosphate bone cement as antibiotic delivery system.

Authors:  M Bohner; J Lemaître; P Van Landuyt; P Y Zambelli; H P Merkle; B Gander
Journal:  J Pharm Sci       Date:  1997-05       Impact factor: 3.534

5.  Characterization and heterologous expression of a class IIa bacteriocin, plantaricin 423 from Lactobacillus plantarum 423, in Saccharomyces cerevisiae.

Authors:  C A Van Reenen; M L Chikindas; W H Van Zyl; L M T Dicks
Journal:  Int J Food Microbiol       Date:  2003-02-25       Impact factor: 5.277

6.  A class IIa peptide from Enterococcus mundtii inhibits bacteria associated with otitis media.

Authors:  H Knoetze; S D Todorov; L M T Dicks
Journal:  Int J Antimicrob Agents       Date:  2007-12-26       Impact factor: 5.283

7.  Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model.

Authors:  Danuta Kruszewska; Hans-Georg Sahl; Gabriele Bierbaum; Ulrike Pag; Sean O Hynes; Asa Ljungh
Journal:  J Antimicrob Chemother       Date:  2004-07-28       Impact factor: 5.790

8.  Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus.

Authors:  M De Kwaadsteniet; K T Doeschate; L M T Dicks
Journal:  Lett Appl Microbiol       Date:  2008-11-14       Impact factor: 2.858

9.  Ionic modification of calcium phosphate cement viscosity. Part II: hypodermic injection and strength improvement of brushite cement.

Authors:  J E Barralet; L M Grover; U Gbureck
Journal:  Biomaterials       Date:  2004-05       Impact factor: 12.479

10.  Bioengineering of a Nisin A-producing Lactococcus lactis to create isogenic strains producing the natural variants Nisin F, Q and Z.

Authors:  Clare Piper; Colin Hill; Paul D Cotter; R Paul Ross
Journal:  Microb Biotechnol       Date:  2010-09-08       Impact factor: 5.813

View more
  1 in total

Review 1.  Using bacterial genomes and essential genes for the development of new antibiotics.

Authors:  Francisco R Fields; Shaun W Lee; Michael J McConnell
Journal:  Biochem Pharmacol       Date:  2016-12-08       Impact factor: 5.858

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.